Connection
Theodore Karrison to Research Design
This is a "connection" page, showing publications Theodore Karrison has written about Research Design.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.785 |
|
|
|
-
Karrison T, Kocherginsky M. Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials. 2018 04; 15(2):178-188.
Score: 0.532
-
Dignam JJ, Karrison TG. Building firm foundations for therapy development. J Natl Cancer Inst. 2015 Mar; 107(3).
Score: 0.431
-
Kocherginsky M, Cohen EE, Karrison T. Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents. J Biopharm Stat. 2009; 19(3):524-9.
Score: 0.282
-
Ratain MJ, Karrison TG. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res. 2007 Feb 01; 13(3):781-2.
Score: 0.246
-
Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, Stadler WM, Ratain MJ. Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.
Score: 0.087
-
Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61.
Score: 0.064
-
Chappell R, Karrison T. Continuous Bayesian adaptive randomization based on event times with covariates by Cheung et al., Statistics in Medicine 2006; 25:55-70. Stat Med. 2007 Jul 10; 26(15):3050-2; author reply 3052-4.
Score: 0.064
-
Karrison TG, Huo D, Chappell R. A group sequential, response-adaptive design for randomized clinical trials. Control Clin Trials. 2003 Oct; 24(5):506-22.
Score: 0.049
-
Karrison TG. Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations. Control Clin Trials. 1997 Apr; 18(2):151-67.
Score: 0.031